Chico's FAS Statistics
Total Valuation
Theraclion has a market cap or net worth of 29.40 million. The enterprise value is 33.37 million.
| Market Cap | 29.40M |
| Enterprise Value | 33.37M |
Important Dates
The next estimated earnings date is Wednesday, October 29, 2025.
| Earnings Date | Oct 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 45.68M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +1.16% |
| Shares Change (QoQ) | +2.59% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 24.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 34.20 |
| PB Ratio | -249,150.03 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.60 |
| EV / Sales | 34.56 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -10.70 |
Financial Position
The company has a current ratio of 2.55
| Current Ratio | 2.55 |
| Quick Ratio | 1.87 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.52 |
| Interest Coverage | -316.61 |
Financial Efficiency
Return on equity (ROE) is -203.90% and return on invested capital (ROIC) is -39.71%.
| Return on Equity (ROE) | -203.90% |
| Return on Assets (ROA) | -28.29% |
| Return on Invested Capital (ROIC) | -39.71% |
| Return on Capital Employed (ROCE) | -82.96% |
| Revenue Per Employee | 26,860 |
| Profits Per Employee | -186,261 |
| Employee Count | 32 |
| Asset Turnover | 0.06 |
| Inventory Turnover | 1.80 |
Taxes
| Income Tax | -1.02M |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | -0.01 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 2,367 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Theraclion had revenue of 859,519 and -5.96 million in losses. Loss per share was -0.13.
| Revenue | 859,519 |
| Gross Profit | -3.96M |
| Operating Income | -7.06M |
| Pretax Income | -6.98M |
| Net Income | -5.96M |
| EBITDA | -6.73M |
| EBIT | -7.06M |
| Loss Per Share | -0.13 |
Balance Sheet
The company has 4.32 million in cash and 7.85 million in debt, giving a net cash position of -3.53 million.
| Cash & Cash Equivalents | 4.32M |
| Total Debt | 7.85M |
| Net Cash | -3.53M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -118 |
| Book Value Per Share | -0.00 |
| Working Capital | 5.20M |
Cash Flow
In the last 12 months, operating cash flow was -3.01 million and capital expenditures -105,601, giving a free cash flow of -3.12 million.
| Operating Cash Flow | -3.01M |
| Capital Expenditures | -105,601 |
| Free Cash Flow | -3.12M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -821.37% |
| Pretax Margin | -811.94% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Theraclion does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.16% |
| Shareholder Yield | n/a |
| Earnings Yield | -20.27% |
| FCF Yield | -10.61% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Theraclion has an Altman Z-Score of -1.17 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.17 |
| Piotroski F-Score | 2 |